Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B/2A, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Treatment With, Or Who Cannot Tolerate Omalizumab

Next Previous
Trial Profile

A Phase 1B/2A, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Treatment With, Or Who Cannot Tolerate Omalizumab

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Briquilimab (Primary)
  • Indications Chronic urticaria
  • Focus Adverse reactions
  • Acronyms BEACON
  • Sponsors Jasper Therapeutics

Most Recent Events

  • 12 May 2025 According to a Jasper Therapeutics media release, the company will present the updated data from this study in the first half of Q3 2025
  • 01 Mar 2025 Initial results presented in the Jasper Therapeutics Media Release.
  • 01 Mar 2025 According to a Jasper Therapeutics media release, Company is presenting updated clinical data from the Phase 1b/2a BEACON study, as well as data from four preclinical studies evaluating briquilimab, at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top